Another probable case of monkeypox has been found in a Santa Clara County resident, the county Public Health Department said Thursday.
The case is not connected to a previous case, which health authorities announced on June 23. If confirmed, it would be the second monkeypox case in the county. The person preliminarily tested positive for monkeypox virus after seeking medical care and is in isolation, the department said in a June 30 statement.
The case was reported to the department as required by law, and confirmation of monkeypox is pending testing by the Centers for Disease Control and Prevention, the county said. Public health staff are contacting all individuals who might have come in contact with the person while they were contagious.
The department is working with local medical providers to increase their awareness of the symptoms of monkeypox, how to prevent transmission and appropriate reporting to state and local health authorities.
Monkeypox is a rare disease. Symptoms typically include a fever, intense headache, muscle aches, back pain, low energy, swollen lymph nodes and a skin rash or lesions. The rash usually begins within one to three days of the start of a fever. Lesions can be flat or slightly raised, filled with clear or yellowish fluid, and can then crust, dry up and fall off. The number of lesions range from a few to several thousand. The rash tends to be concentrated on the face, palms of the hands and soles of the feet, but can also be found on the mouth, genitals and eyes. It can last for two to four weeks, according to the World Health Organization.
Anyone who is concerned they have symptoms of monkeypox, such as characteristic rashes or lesions, should contact your doctor right away, the health department said.
The county's first case of monkeypox was found in an international traveler.
As of Wednesday, June 29, the CDC has received 350 reports of monkeypox cases in the U.S., primarily among men who have sex with men. The Department of Health and Human Services on Friday ordered an additional 2.5 million doses of Bavarian Nordic's Jynneos, an FDA-licensed vaccine indicated for prevention of smallpox and monkeypox, for use in responding to current or future monkeypox outbreaks, the White House announced.